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Background: The large scale-up of paediatric HIV care necessitated down-referral of 
many children receiving antiretroviral therapy (ART) from Red Cross War Memorial 
Children’s Hospital (RCWMCH). No published data exists on the outcomes of these 
children.  
 
Objectives:  To assess clinical, immunological and virological outcomes of children 
receiving ART in the first 12 months after down-referral to primary health care (PHC) 
clinics, and identify determinants of successful down-referral. 
 
Methods: We conducted a retrospective cohort study of children <15 years of age 
who commenced ART at RCWMCH and were subsequently down-referred to one of 
two PHC clinics between January 2006 and December 2012.  Baseline characteristics 
of patients and caregivers as well as CD4 counts, viral loads and weights were 
collected at 6 and 12 months post-down-referral. Outcomes included retention in care 
and viral suppression.  
 
Results: One hundred and sixteen children down-referred to Heideveld and 
Gugulethu were included. After down-referral 13.8% of the cohort never arrived at 
the designated clinic and 10% took longer than 8 weeks, therefore probably 
experiencing treatment interruption. At 12 months post down-referral only 68.2% 
remained in care at the designated clinics. No factors were associated with retention 
in care. For those children who remained in care at the PHC clinics, the clinical and 
immunological gains achieved prior to down-referral were sustained through 12 
months of follow up, and 54.7% of the retained cohort had documented viral 
suppression at 12 months.   
 
Conclusion: Down-referral of children on ART is a vulnerable process with risk of 
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The HIV/AIDS epidemic has had a dramatic impact on the health of South Africa’s 
children, contributing substantial morbidity and mortality. Without antiretroviral 
therapy (ART) more than 50% of perinatally infected children will die before their 
second birthday1. The South African national ART programme was launched in April 
2004, and is now the biggest programme in the world with over 3 million people 
receiving ART2. Although paediatric coverage has increased from just over 9% in 
2004/20053 to 63% by the end of 2012, the treatment gap favouring adults has 
persisted in South Africa, as in many other low- and middle-income countries4. 
Paediatric treatment programmes suffered from many of the same barriers to 
improving ART coverage as adult programmes, including human resource and health 
facility limitations – which were more pronounced in rural areas. In the push for a 
rapid scale-up of ART provision and improvement in ART coverage, the South 
African government adopted the  ‘public health’ approach to HIV care that the WHO 
had been promoting since 20015. Central to this approach are the two closely linked 
concepts of task shifting and decentralization. Task shifting entails ‘lower’ cadres of 
health care providers, and sometimes non-professionals, taking over responsibilities 
previously held by doctors or ‘higher’ cadres of health care workers6. Decentralizing 
care is the process of moving care from tertiary referral centres to health care centres, 
clinics, and even beyond clinics into communities  - closer to patient’s places of 
residence7.  For many patients, particularly those already receiving care from tertiary 
hospitals this has required a process of ‘down-referral’ to treatment sites with less 
specialized health care facilities.   
 
By 2007/2008 the Western Cape paediatric ART coverage rate had improved to over 
95%, well exceeding the national average of 37%8. This was a consequence of both 
significant gains in preventing mother-to-child-transmission of HIV as well as 
expansion of the paediatric HIV programme into primary health care (PHC) settings. 
This decentralized model of care necessitated the down-referral of large numbers of 
children from tertiary academic hospitals to community-based clinics. To date there is 
very little data on the outcomes of down-referred children worldwide, and the cohort 
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from Red Cross War Memorial Children’s Hospital (RCWMCH) specifically, has 
never been studied.  
Objective 
The objective of this literature review is to assess the impact of decentralizing 
paediatric ART provision by down-referral of patients from tertiary centres to PHC 
clinics.  
Search strategy 
The issues around scale-up of ART provision, and down-referral of patients are 
relatively new, thus published data and research are limited. A broad search was 
therefore conducted on a number of database platforms: 
• Pubmed
• Ebscohost
• Web of Science
• The Cochrane database.
The abstract archive of the International Aids Society (http://www.abstract-
archive.org/) was also searched for relevant unpublished research.  
Search terms used included MeSh terms and free text: 
• HIV, Child, Paediatric/ pediatric, decentralization, “down-referral” and “transfer
out.”
The bibliographies of relevant articles were also searched for additional papers.  
The search was originally done in June 2012 and then repeated in January 2016 prior 





Acceptable studies/ inclusion criteria 
As the evidence is so limited inclusion criteria were deliberately left broad:  
 
Population: Adults and children 
Intervention: A process of down-referral or decentralization of HIV care 
Comparator: Retention in care at site of initiation 




Despite the broad search strategy and inclusion criteria, data were limited.  
From the Cochrane database there was one systematic review of decentralized care, 
looking at outcomes in both adults and children. There were 7 further studies looking 
at outcomes in decentralized models of HIV care in adults and children, and only 2 
studies that looked exclusively at outcomes of down-referred paediatric patients.  
 
A further 12 articles were included in this review as they relate broadly to the topic of 






Down-referral is a small component of the larger policy of creating a decentralized 
model of care for HIV-infected patients. Before being able to assess the impact of the 
down-referral process, one first needs to ascertain whether patient outcomes at the 
various different levels of care are comparable. 
 
Outcomes at different levels of care – adult data 
Evidence from the adult literature suggests that treatment outcomes at primary health 
care clinics are at least as good if not better than at tertiary hospitals. In a 
retrospective cohort study of over 29 000 ART naive adults who commenced ART at 
one of 59 treatment centres in South Africa, Fatti et al. report superior outcomes at 
PHC facilities9. Despite having more advanced clinical stage of disease at the time of 
initiation, no significant differences in mortality rates after 24 months of treatment 
could be found between patients at PHC clinics and those managed at secondary and 
tertiary hospitals9. Furthermore, patients managed at PHC clinics had less loss to 
follow up (LTFU) at 24 months of treatment (8.9% vs. 17.9%), and greater retention 
in care (80.1% vs. 68%) than patients managed at secondary and tertiary hospitals. A 
similar sized study assessing decentralization of HIV care in Kenya, also found no 
difference in mortality rates between patients managed at primary or secondary health 
facilities10. In contrast to the South African study, this study found no significant 
difference in rates of LTFU of patients on ART. Both studies, thus providing evidence 
of equitable outcomes for HIV-infected adults managed at different levels of health 
care.  
 
There are a number of unique issues in the management of HIV-infected children that 
make it impossible to generalise from the adult data. Rates of adherence and loss to 
follow up are governed by a child’s caregiver – on whom they are entirely dependent. 
In this context, caregivers are often HIV-infected themselves with varying degrees of 
health, or they are elderly family members caring for an orphaned child. Another 
obstacle is the large number of medications, some unpalatable, that the child is 
required to take11. These differences between adult and paediatric care make it 
imperative to assess paediatric outcomes independently.     
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Outcomes at different levels of care – paediatric data 
There are two studies that have compared treatment outcomes of children on ART 
between different levels of care. In a 2007 study, Bock et al. conducted a retrospective 
review of routinely collected data from a cohort of children in the Western Cape who 
had initiated ART between April 2004 and April 200612. Of the 1741 children, 20.7% 
were managed at primary health care (PHC) level, 13.6% at district hospital level, and 
65.7% at level 2 & 3 hospitals. Overall 46% of the cohort commenced ART with 
severe immunodeficiency with CD4 counts < 15%. Survival estimates at 12 months 
after commencing ART were 0.88 (95% CI: 0.86 – 0.9) at level 2 &3 hospitals, and 
0.94 (95% CI: 0.89-0.97) and 0.94 (95% CI: 0.89 – 0.9) at both PHC and district 
hospitals respectively. Rates of death at 12 months were 13.2% (95% CI: 10.3- 16.5) 
and 2.6% (95% CI: 0.5 – 6.9) at level 2 & 3 hospitals and PHC clinics respectively.  
The percentage of children with suppressed viral loads (defined as <400 copies/ml) 
after 12 months of treatment with combination ART was 70.5% (95% CI: 64.9 – 75.9) 
at level 2 &3 hospitals, and 81.4% (95% CI: 72.4 – 88.4) at PHC clinics.  This data 
suggests that children receiving combined ART from PHC clinics do no worse – and 
possibly better than children at secondary and tertiary hospitals.   
Fayorsey et al.13 reached similar conclusions in their study of 8475 children from 5 
sub-Saharan African countries. They retrospectively reviewed routinely collected 
programmatic data from 274 health facilities in Kenya, Rwanda, Tanzania, Lesotho 
and Mozambique. Between January 2008 and March 2010, 17155 children under the 
age of 15 enrolled in HIV care, 8475 of whom were initiated on ART. During the 
study period, the majority (71%) of children who were initiated on ART, did so at 
secondary/ tertiary health facilities (SHFs) rather than at primary health facilities 
(PHFs). There was, however, a significant trend towards decentralizing paediatric 
HIV care over the two year period. The number of PHFs providing HIV care to 
children increased threefold, from 56 to 182, in comparison to an increase of SHFs 
from 72 to 92. This accounts for a 22.6% increase in the contribution of PHFs to the 
total number of centres providing paediatric HIV care. As the number of PHFs 
increased, so to did the contribution they made to initiating and maintaining children 
on ART.  Every quarter an increasing number of children were initiated on ART at 
PHFs – an increase of 2.8 times over the 2 years of the study. Rates of mortality and 




9.8/100 PY vs 20.2/100 PY (p=0.003) at PHFs and SHFs respectively. This study, 
while not addressing the issue of ‘transfer-out’, does provide further support for the 
process of decentralizing paediatric HIV care, with evidence of superior outcomes at 
PHFs.   
 
Down-referral of patients on ART – adult data 
As the decentralization of HIV care gained momentum a number of studies started to 
look specifically at the outcomes of patients who were ‘transferred-out’ or ‘down-
referred’ from one health care facility to lower levels of care.  Three South African 
studies reported positive outcomes for down-referral of adults on ART. O’Connor et 
al. reported extremely high rates of retention in care from a cohort of 3361 patients in 
an inner city Johannesburg treatment service14. Patients became eligible for down-
referral to one of four nurse-managed PHC clinics once they were clinically stable, 
with improving CD4 counts and undetectable viral loads, good adherence and on 
ART for at least 6 months (mean 1.56 years). Patients who missed their scheduled 
appointments by more than 6 weeks were aggressively traced, initially telephonically, 
and then by home based care workers. During the study period only 4.1% of patients 
were LTFU, 95.5% were retained in care (of whom, 3% were receiving care outside 
of the down-referral programme) and less than 1% of patients retained in care had 
been transferred back to the treatment initiation site. Unfortunately this paper 
provides no information about the duration of follow up after down-referral, and this 
would likely introduce bias in favour of down-referral if the follow up time at PHC 
facilities was low. Importantly however, of those patients who were lost to follow up, 
58% never arrived at the down-referral site – hinting at the vulnerability of this 
process of transferring patients between treatment sites. Finally, this study did not 
evaluate clinical, immunological or virological outcomes after down-referral. Despite 
good retention in care it is thus impossible to comment on the quality of the care 
provided.   
 
Comparably high rates of retention in care were reported from another inner city 
Johannesburg treatment site after down-referral from a doctor-managed HIV clinic to 
a nurse-managed PHC clinic. In this setting, patients became eligible for down-
referral only after 11 months of ART, with evidence of good adherence (2 suppressed 
viral loads, CD4 > 200 cells/µl) and clinical stability (<5% weight loss over last 3 
13	
visits and no opportunistic infections)15. Of the patients who met down-referral 
criteria, less than 35% were actually transferred out. Some patients were not offered 
down-referral and others refused, both for undocumented reasons. This low rate of 
uptake of down-referral has the potential to bias outcomes in favour of the down-
referral model. The two sites in this study (the ‘treatment initiation’ site and the 
down-referral site) were closely integrated through an electronic patient management 
system. This allowed for easy transfer of patient medical records between the sites, as 
well as system alerts to remind the provider when patients were eligible for down-
referral or required referral back to the treatment initiation site15. In a matched-cohort 
analysis of those patients who were down-referred and those who were retained at the 
treatment initiation site, better outcomes were reported at the nurse-managed down-
referral clinic. Twelve months after down-referral eligibility, loss to follow up was 
1.4% vs. 4.2%, mortality rates were 0.3% vs. 1.5% and rates of virological rebound 
were 3.3% vs. 5.6% in the down-referred and non down-referred groups respectively.  
In the same treatment setting, Long et al. focused on the cost saving benefits of down-
referral16.  They report a financial saving of 11% per patient per year. This saving 
persists despite 17% of transferred patients having been transferred back to the 
treatment initiation site within an average of 6.1 months post down-referral.  
One South African study reported higher rates of LTFU in patients down-referred 
from a doctor-managed ART clinic to a nurse-managed programme in a peri-urban 
community health center in Gugulethu, Cape Town17. Down-referral criteria in this 
study included at least 16 weeks of first line ART therapy, a recent viral load <50 
copies/ml, no opportunistic infections or poorly controlled chronic illnesses, and 
documented adherence based on pill counts. Data were collected prospectively on 
5746 patients, and the primary outcomes measured included death, LTFU and 
virological failure17. The study found no significant differences in either mortality 
[aHR 1.51 (95% CI: 0.9 – 2.55)] or virological failure [aHR 0.94 (95% CI: 0.78 – 
1.13)] between the down-referred and non down-referred groups. In contrast to the 
other three South African studies cited above however, rates of LTFU in this study 
were found to be higher in the down-referred group than those retained at the doctor-
managed clinic [aHR 1.36 (95% CI: 1.09 – 1.69)]. Down-referred patients had fewer 
scheduled clinic appointments, with ART being dispensed at the pharmacy for 2 
months at a time, and clinical follow ups with nursing staff scheduled every 4 months 
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only17. This reduced the opportunities for adherence support and individualized 
counseling. Furthermore, an important difference in this study is that the treatment 
initiation site and the down-referral clinic were both located on the same physical 
grounds at the Gugulethu CHC.  This would diminish the positive effect of the 
advantages of down-referral such as accessibility and reduced travel times. 
Furthermore it becomes unclear whether the measured effect is secondary to down-
referral or task- shifting.  
A final study that looked at the effects of decentralizing access to antiretroviral 
therapy for adults was conducted in Swaziland. This study compared rates of LTFU 
and death amongst patients whose ART was either partially or fully decentralized 
with those whose care was maintained at central treatment initiation sites (hubs)18. 
Partial decentralization was defined as patients who initiated ART at hubs and were 
subsequently down-referred to PHC clinics (spokes). Full decentralization of care was 
achieved if ART was initiated at spokes.  In both models of care ART initiation was 
done by doctors, and ongoing care at PHC clinics was provided by nurses. The overall 
rates of death and LTFU at 1 year after ART initiation in this study were 3% and 16% 
respectively. Down-referral was strongly protective against LTFU [aHR 0.38 (95% 
CI: 0.29 – 0.50)] but not mortality.  
Down-referral of patients on ART  - studies combining adult and paediatric data  
Further evidence in favour of down-referral of HIV care comes from two studies from 
Malawi. Importantly, both of these studies included both adults and children in their 
analyses. As in South Africa, the large scale-up of ART provision in Malawi was 
hindered by both financial and human resource constraints. Furthermore the 
centralization of care was thought to contribute to the suboptimal reported rates of 
retention in care, and to increase inequality in health care provision for poor rural 
communities19. Consequently the process of decentralization of ART provision began.  
In a retrospective review of 4175 patients (10% of whom were children) commencing 
ART over a three year period in Mzuzu Central Hospital in Northern Malawi, 19% 
were found to have been transferred out20.  Of the transferred out cohort – 92% were 
traced, and of these patients, 90% were found to have transferred in to a new 
treatment centre. The median time between transfer out and transfer in was just over 1 
month, suggesting that patients were unlikely to experience treatment interruptions as 
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a result of the transfer process20. In this study there was no significant difference 
between rates of loss to follow up between those transferred out and those retained in 
centralized care, however those transferred out had significantly lower mortality rates 
[OR 0.4 (95% CI: 0.3 – 0.6)]. 
In the mostly rural Zomba district in Southern Malawi, decentralization of HIV care 
was achieved through incorporation into routine outpatient services at rural health 
centres19.  In a retrospective review of 8093 patients who commenced ART over a 4 
year period, 4653 were retained at the central hospital site, and 3440 were 
‘decentralized’ to health centres, this included 1005 (29%) patients who were 
managed solely at the decentralized site (i.e. not down-referred.) In this cohort of 
patients, decentralization of care was associated with lower rates of mortality [OR 
0.19 (95% CI: 0.15 – 0.25)] and defaulting from care [OR 0.28 (95% CI: 0.4 – 
0.58)]19. Although the data from this second study includes both patients who were 
down-referred as well as some who exclusively managed at peripheral health centres, 
it still lends further support to the model of decentralization and down-referral of HIV 
care.  
Down-referral of patients on ART  - paediatric data 
Only two studies have looked exclusively at the outcomes of down-referral of 
children receiving ART. Despite significant differences in the setting and the design 
of these studies – both reported good clinical and virological outcomes. In a Thai 
study, the outcomes of 168 children who were down-referred from a centralized 
tertiary hospital to 1 of 16 ‘community hospitals’ were reviewed. Community 
hospitals had at least 2 healthcare professionals, including doctors, nurses and 
pharmacists as well as people living with HIV, who did home visits and adherence 
counseling21. After down-referral, close relations were maintained between the 
tertiary and community hospitals – with teleconferences and individual case reviews. 
Furthermore, children returned to the tertiary centre for review by a paediatrician 
every 6 months21.  Down-referral criteria in this cohort included being clinically 
stable, with no opportunistic infection, improving weight and CD4 counts, as well as 
having a willing caregiver.  Interestingly, as this study was conducted shortly after the 
implementation of the Thai national ART programme, the participants tended to be 




entire cohort had a CD4 count of less than 5% at initiation21). Despite this, the rates of 
retention in care and adherence are impressive. Of the 168 children down referred to 
community hospitals, with a median follow up time of 18 months, only 6 children 
(3.5%) were referred back to the tertiary hospital for continuation of care and no 
children were lost to follow up21.  Adherence in the entire cohort was >95% 
(measured on pill counts or volume measurements) over 48 months of follow up, with 
no significant difference between the down-referred or the retained in care groups. 
During the study period 10% of the cohort died, representing a crude mortality rate of 
4.1/100 PY of follow up (95% CI: 3 – 5.6). Of these deaths, 60% were reported in the 
first 90 days of treatment, and none of the deaths were in the down-referred group21. 
This reflects both the stability of the patients chosen for down-referral and the length 
of time on treatment before down-referral. When the programme started, time to 
down-referral was 31 months, but for children who started ART after September 2006 
the time had reduced to 8 months.  
 
Clinical and virological outcomes were comparable between the 2 groups. Children 
from the down-referred group initiated ART from a lower weight-for-age z-score 
(WAZ) baseline than those retained in care (median WAZ -2.1 vs. -1.6, p = 0.001). 
There was however, no difference in the rate of weight gain between the two groups. 
The median CD4% increased from 6% at baseline to 26% at 48 months of follow up, 
and the number of children with a CD4% below 15% declined from 80% to 4.8% in 
the same time frame. Again there was no significant difference between the two 
groups.  The number of children with serial viral loads available was limited, however 
of those available, >86% of children who were ART naïve at initiation had 
undetectable viral loads (less than 400 copies/ml) at 48 months of follow up. This 
study has shown that with high levels of support – both within the community for 
patients and their caregivers, as well as at the down-referral sites for the treating 
health professionals, that highly successful outcomes for a decentralized model of 
paediatric HIV care are possible. The older age of the cohort, the small numbers 
treated at each community hospital, as well as the intensive adherence monitoring and 
counseling makes it unclear if the results of this study could be generalized to a South 
African context.  
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In 2014 Morsheimer et al. published their findings of a cohort of down-referred 
children in the Western Cape, South Africa22. This study differs from the Thai study, 
as well as from many of the adult studies, in that down-referred patients were 
identified at the PHC clinic rather than at the site of ART initiation, and then 
compared to patients who were initiated at the same PHC clinic. Thus the outcomes of 
any patients who were lost during transfer were not captured. The study was done at a 
time when the decentralization of paediatric HIV care was gaining momentum. 
Between March 2004 and September 2006 the percentage of children receiving their 
ART from the three Cape Town tertiary hospitals declined from 78% to 38%, and the 
number of clinics treating children with ART increased from 11 to 4123. 
In this context, Morsheimer et al. conducted a retrospective review of 613 children 
who were either down referred for continuation of ART or initiated on ART at 1 of 
the 7 community-based paediatric ART clinics supported by the paediatric infectious 
diseases team from Tygerberg Children’s Hospital.  The median age of the children in 
this study was 26.4 months (IQR 10.2 – 63), substantially lower than the children in 
the Thai study. Of the 613 children included in this cohort, 343 were initiated at the 
PHC clinics, and the remaining 270 had been down-referred from tertiary hospitals. 
For the down-referred group the median follow up time was 28 months. During that 
time only 1 patient required transfer back to the tertiary care site, and 1 patient died 
(0.6%)22.  The down-referred patients were significantly sicker at initiation than those 
who initiated treatment at PHC level; 89.8% of them vs. 70.7% of PHC initiates had 
WHO stage III/IV at initiation (p< 0.0001), they also had higher baseline viral loads  
(median: 326 969 vs. 230 000 copies/ml, p = 0.0004) and increased rates of 
concomitant TB infection at initiation (25.3% vs. 16.9%, p = 0.013)22. It also took 
longer (44 vs. 29 weeks) for those who were down-referred to achieve viral 
suppression (<400 copies/ml). Importantly however, of the 80% of patients who were 
down-referred with suppressed viral loads, 96% showed sustained viral suppression at 
last study evaluation22. Twenty-six patients were down-referred with unsuppressed 
viral loads, many of whom met criteria for virological failure, and most of whom had 
documented concerns of poor adherence.  After 6 months of treatment at the PHC 
site, 77% of these children were able to achieve virological suppression on first line 
ART, avoiding the need to change to second line ART. This is important for a number 
of reasons; firstly it is unique in the literature to have patients down-referred with 
18	
unsuppressed viral loads, as most centres have used viral suppression as a criterion for 
down-referral. Secondly, it challenges the notion that higher levels of care will have 
more success in achieving the desired virological outcomes. Most importantly 
however, it suggests that for those patients where adherence is an issue, outcomes 
may in fact be better at treatment centres closer to home, possibly by reducing the 
barriers to accessing care22.  As with the Thai study, this study has shown good 
treatment outcomes for children down-referred to PHC clinics for continuation of 
their ART.  
Decentralized care: systematic review 
In 2013 Kredo et al. published the first (and to date only) Cochrane review of 
decentralization of HIV care in lower- and middle-income countries7. In this review 
they described three patterns of decentralization: ‘full decentralization’ which entails 
initiation and maintenance of ART at peripheral sites, ‘partial decentralization’- 
commencing ART at central hospitals and then down-referring patients to peripheral 
sites for ongoing care, and ‘community based models’ where ART is commenced in a 
health centre or hospital but is continued in the home environment with support 
provided by health care workers or volunteers7. Sixteen Studies were included in this 
review, 1 from Thailand the other 15 from African countries. The strongest evidence 
was in favour of ‘partial decentralization’ or down-referral. At 12 months of follow 
up, in comparison to remaining in centralized care, the risks of attrition, LTFU and 
death in the down-referred group were RR 0.46 (95% CI 0.29 – 0.71), RR 0.55 (95% 
CI 0.45 – 0.69) and 0.34 (95% CI 0.13 – 0.87) respectively.  This review included 
studies of both adult and paediatric patients, including many of those discussed above. 
Concerns regarding decentralized care 
The literature thus seems conclusive as to the positive benefits of decentralization and 
down-referral in both adult and paediatric populations. There are however, a number 
of studies that highlight significant areas of concern. In 2008 Mukora et al. conducted 
10 focus group discussions with 76 patients receiving ART at Chris Hani 
Baragwanath hospital (CHBH)24. Their aim was to assess patient attitudes to down-
referral of their HIV care from the central CHBH to peripheral PHC clinics in 
Soweto. In these focus group discussions patients acknowledged the advantages of 
down-referral, specifically closer proximity to home with the resultant reduction in 
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transport costs and time at clinic. Despite this, 63% of the participants were opposed 
to down-referral.  They cited concerns of increased stigma and reduced confidentiality 
at peripheral PHC clinics, as well as a preference for continuing doctor led care. 
Furthermore, they expressed uncertainty about the quality of care at the PHC clinics 
and perceived negative nursing attitudes and lack of nurse training in HIV 
management24. Importantly, the patients in this study had no experience of down-
referral as the study took place prior to the implementation of decentralized care.  
A more concerning study was published in 2014 by Ostermann et al.25, which 
evaluated the effect of the rapid scale-up of decentralized HIV care in Northern 
Tanzania. In this prospective cohort study, there was a concerning trend for patients to 
bypass many closer care and treatment centres (CTC’s) in favour of established 
facilities. Despite a large increase in the number of CTC’s in the study area, after 3.5 
year of follow up, only 2% of patients who had been initiated at the referral hospitals 
had been transferred-out, and almost 75% of patients newly enrolling in HIV care did 
so at the referral hospitals25.  Compounding these concerns is a study from rural South 
Africa, which, despite acknowledging the positive outcomes of down-referral, 
highlighted the potential unseen additional health care expenses incurred by down-
referred patients26.  In this study, down-referred patients were 7 times more likely to 
have visited private physicians and 5 times more likely to have engaged in ‘self-care 
practices’ than those retained in care. In 27% vs. 11% of the down-referred and 
retained in care patients respectively, this represented a ‘catastrophic healthcare 
expenditure’.  This increased use of private doctors may be the result of the expressed 
patient preference to be seen by doctors. Regardless of the reason, the increased 
financial burden incurred in the down-referred group raises concerns over 
sustainability and long-term retention in care.  
In a case report study of decentralization of HIV care in Tete city in Mozambique, 
Decroo et al. describe the programmatic consequences of a poorly planned down-
referral process27. In this report, 30% of down-referred patients were lost to follow up. 
This was thought to be secondary to the rapid rate of decentralization and 
inappropriate planning. As a large number of patients were transferred to PHC clinics 
in a short period of time, the capacity and human resources of these clinics were 
rapidly overwhelmed, resulting in long waiting times and unreliable drug supplies27. 
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Unfortunately it is not clear from this report at what stage in the transfer process 
patients were lost to follow up. In a study from central Johannesburg, although the 
overall LTFU rate was only 4.1% almost 60% of these patients were lost at the point 
of transfer out and never presented to the PHC at all14. This suggests that there is an 
intrinsic vulnerability to the process of transferring patients from one treatment site to 
another, and that in order to reduce LTFU, special attention needs to be given to 
managing this event.  
Although there is now a growing body of research and data looking at the issues of 
decentralization, task shifting and down-referral, many concerns and questions still 
remain. In most of the published studies, down-referral was highly selective, not only 
were the patients clinically stable, but they were agreeable to down-referral – this 
could obviously introduce bias in favour of down-referral. Secondly, whilst some 
studies have reported very low rates of transfer back to higher levels of care, some 
have reported rates of up to 17%16. The outcomes of patients who are reluctant to be 
down-referred is still unclear, and in this context the 30% LTFU reported by Decroo 
et al.27 is concerning. Furthermore, in a number of the studies that report very good 
treatment outcomes post down-referral, the level of interaction and integration 
between the central hospital and the down-referral sites far exceeds that available in 
other resource poor settings. In some studies this is by way of physical proximity, 
electronic patient management systems or regular contact and case discussions 
between care providers in the different settings15,21.  In the two published paediatric 
studies, although there was definite decentralization and down-referral, there was less 
task shifting. In the Thai study21, patient management was still ultimately controlled 
by the specialist in the referral hospital, and in the South African study22, patients in 
the PHC were seen by specialist doctors trained in paediatric HIV care. Finally, 
although clinical and virological stability have been used as prerequisites in most 
studies – there is some evidence of benefit in down-referring those patients with 
adherence issues, thus the question of down-referral criteria and optimal timing of 
down-referral still need to be answered.  
Down-referral is a central component of the package of care provided by the 
RCWMCH paediatric HIV programme. To date, no assessment has been made of the 




attempted. As illustrated above, the available evidence from paediatric data is 
severely limited, and conclusions are not necessarily generalizable to this cohort of 
patients. RCWMCH down-refers large numbers of patients for ongoing HIV care. It is 
imperative that we try to understand the effect that this transition has on our patients, 
and whether they are, in fact, able to safely navigate the down-referral process 
without ill effect.   
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Table 1: Summary of Literature 
Study Setting Design Study population Outcomes 
Outcomes at different levels of care: 
Adults 
Fatti G et al.9 
(2010) 
South Africa • Retrospective cohort
• Multi-centre
• Comparing outcomes at PHC facilities,
district and regional hospitals
29 203 adults 
ART naïve 
Better outcomes at PHC: 
• Retention in care at 2 years: 80% at PHC, 68% at regional hospital 
• LTFU increased at regional hospitals at 1 year: aHR 2.19 (95% CI: 1.94 – 2.42)
• Mortality increased at district hospitals at 1 year: aHR 1.6 (95% CI: 1.33 – 1.99)
• Reduced probability of virological suppression at district and regional hospital
compared to PHC: aOR 0.76 (95% CI: 0.59-0.97) and 0.64 (95% CI: 0.56 – 0.75)
Reidy W et al.10 
(2014) 
Kenya • Prospective cohort
• Multi-centre
• Comparing outcomes at PHFs and SHFs
26690 adults At least comparable outcomes:  
• Less LTFU at 6 months post initiation at PHFs (7.4% vs. 4.7%)
• No significant difference in mortality between PHFs and SHFs
Paediatrics 





• Comparing outcomes at PHC facilities,
level 1 hospitals and level 2 & 3 hospitals
1741 children 
<15yrs old 
At least comparable outcomes:  
• Less attrition at PHCs and district hospitals than level 2&3 – not significant
• No significant difference in LTFU at 6 &12 months
• No significant difference in viral suppression 







• Comparing outcomes at PHFs and SHFs
8475 children 
< 15yrs old 
Better outcomes at PHFs: 
• Less LTFU at 12 months post initiation at PHFs (9.8/100 PYs)
than SHFs (20.2/100PYs)
• Lower mortality rates at PHFs (5.2/100PYs) than SHFs (6/100PYs)
Outcomes after down-referral: 
Adults 






• Reporting on outcomes of down-referred
patients
3361 adults • High rates of retention in care post down-referral (95%)
• Of those patients LTFU – 58% lost at the point of down-referral




• Retrospective matched cohort
• Single centre
• Comparing outcomes of down-referred




2079 retained at 
initiation site 
Better outcomes in down-referred group:  
• Lower rates of LTFU: 1.4% vs. 4.2% at 12 months of follow up
• Lower mortality rates: aHR 0.2 (95% CI: 0.04 – 0.8)
• Lower rates of viral rebound: 3.3% vs. 5.6% at 12 months of follow up




• Retrospective matched cohort
• Single centre
• Comparing outcomes of down-referred




2136 retained at 
initiation site 
Better outcomes in down-referred group:  
• Comparably high rates of retention in care (>90% in both groups)
• Less attrition in down-referred group: RR 0.27 (95% CI: 0.15 – 0.49)
• Cost saving of 11% in down-referred group
• High rates of referral back to treatment initiation site in down-referred group (17% in
12 month)
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Study Setting Design Study population Outcomes 
Outcomes after down-referral: 
Adults 






• Comparing outcomes of patients down-
referred to nurse-managed clinic to those
retained at doctor-managed clinic.
5746 adults: 
2341 down-referred 
3405 retained at 
treatment initiation site 
• Higher rates of LTFU in down-referred group: aHR 1.36 (95% CI: 1.09 – 1.69)
• Comparable rates of mortality: aHR 1.51 (95% CI: 0.9 – 2.55)
Comparable rates of virological failure: aHR 0.94 (95% CI: 0.78 – 1.13)
Auld AF et al. 18 
(2015) 
Swaziland • Retrospective cohort study
• Multi-centre
• Comparing outcomes of patients
initiated and maintained on ART at
central initiation facilities (hubs), those
down-referred to PHCs (spokes), and




1149 retained at ‘hubs’ 
483 initiated at hubs 
with no associated 
‘spokes’ 
511 initiated at 
‘spokes’ 
Better outcomes at PHC clinics: 
Of those initiated at ‘hubs’, better outcomes in down-referred group than maintained 
group: 
• Lower rates of LTFU aHR 0.35 (95% CI: 0.29 – 0.5)
• Lower rates of attrition aHR 0.50 (95% CI: 0.34 – 0.76)
• Comparable rates of mortality
Better outcomes in those initiated at ‘spokes’ vs. those initiated and maintained at
‘hubs’ 
• Lower rates of LTFU: aHR 0.59 (95% CI: 0.45 – 0.77)
• Lower rates of attrition: aHR 0.60 (95% CI: 0.47 – 0.77)
Comparable rates of mortality
Paediatrics 
Hansudewechakul R et 
al.21  
(2012) 
Thailand • Retrospective cohort
• Single paediatric HIV care network (1
tertiary hospital, 16 community
hospitals)
• Intensive community support post down-
referral 
• Comparing outcomes of down-referred
patients to a ‘retained in care’ cohort
410 Children: 
169 down-referred 
241 retained in 3° care 
Median age at 
initiation: 8.6 years 
Comparable outcomes post down-referral: 
• No LTFU in study period in either group
• No difference in rate of improvement in CD4% or WAZ score
• 3.5% down-referred patients referred back to 3° care





• Multi-site (7 PHC clinics)
• Comparing outcomes of down-referred
patients to those who initiated ART at
PHC
613 Children: 
343 initiated at PHC 
270 down-referred 
Median age at 
initiation: 2.2 years 
Comparable outcomes: 
• No difference in mortality once PHC initiates were on ART >6 months
• Virological suppression attained within 6 months in 77% of patients down-
referred with unsuppressed viral loads.
• Low rates of referral back to 3° care: 0.37%
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PHC: Primary healthcare. PHF: Primary health facility SHF: Secondary/tertiary health facility aHR: adjusted hazards ratio aOR: adjusted odds ratio LIMC: Lower- and middle-income countries 
Study Setting Design Study population Outcomes 
Outcomes after down-referral: 
Both 
Yu J et al.20 
(2008) 
Malawi • Retrospective cohort
• Single-centre
• Comparing outcomes of down-referred
patients to a ‘retained in care’ cohort
4175 patients:  
805 down-referred 
3370 retained in care 
Included 477 children 
(11% of cohort) 
At least comparable outcomes:  
• No significant difference in rates of LTFU or retention in care.
• Lower rates of mortality in down-referred group (5% vs. 12.5% p<0.001)
• Median interval between down-referral and transfer-in to new site 1.3 months
– therefore likely no treatment interruption during transfer process
Chan A et al.19 
(2010) 
Malawi • Retrospective cohort
• Single-centre (1 tertiary hospital, 16
rural health centres) 
• Comparing outcomes of down-referred
patients to a ‘retained in care’ cohort
8093 patients 
3440 decentralized 
Included 778 children 
(10% of cohort) 
Better outcomes in down-referred group:  
• Lower rates of LTFU: aOR 0.48 (95% CI: 0.40 – 0.58)
• Lower rates of mortality: aOR 0.19 (95% CI: 0.15 – 0.25)
Systematic review 
Kredo T et al.7 
(2013) 
LIMC • Systematic review
• 16 studies included (15 from Africa)
• 14 cohort studies, 2 cluster randomised
trials
39090 patients  
(for analysis of ‘partial 
decentralization’) 
Best outcomes associated with ‘partial decentralisation’ – treatment initiation at 
hospital level with subsequent down-referral: 
• Lowest rates of attrition: RR 0.46% (95% CI: 0.29 – 0.71) – moderate quality
evidence
• Lower rates of LTFU: RR 0.55 (95% CI: 0.45 – 0.69)
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Abstract 
Background: The large scale-up of paediatric HIV care necessitated down-referral of 
many children receiving antiretroviral therapy (ART) from Red Cross War Memorial 
Children’s Hospital (RCWMCH). No published data exists on the outcomes of these 
children.  
Objectives:  To assess clinical, immunological and virological outcomes of children 
receiving ART in the first 12 months after down-referral to primary health care (PHC) 
clinics, and identify determinants of successful down-referral. 
Methods: We conducted a retrospective cohort study of children <15 years of age 
who commenced ART at RCWMCH and were subsequently down-referred to one of 
two PHC clinics between January 2006 and December 2012.  Baseline characteristics 
of patients and caregivers as well as CD4 counts, viral loads and weights were 
collected at 6 and 12 months post-down-referral. Outcomes included retention in care 
and viral suppression.  
Results: One hundred and sixteen children down-referred to Heideveld and  
Gugulethu were included. After down-referral 13.8% of the cohort never arrived at 
the designated clinic, and 10% took longer than 8 weeks, therefore probably 
experiencing treatment interruption. At 12 months post down-referral only 68.2% 
remained in care at the designated clinics. No factors were associated with retention 
in care. For those children who remained in care at the PHC clinics, the clinical and 
immunological gains achieved prior to down-referral were sustained through 12 
months of follow up, and 54.7% of the retained cohort had documented viral 
suppression at 12 months.   
Conclusion: Down-referral of children on ART is a vulnerable process with risk of 





The HIV/AIDS epidemic has had a dramatic impact on the health of South Africa’s 
children, contributing substantial morbidity and mortality. Without antiretroviral 
therapy (ART) it is estimated that more than 50% of perinatally infected children will 
die before their second birthday.[1] The South African national ART programme was 
launched in April 2004, and is now the biggest programme in the world with over 3 
million people receiving ART, including an estimated 160 000 children. Since its 
inception, the national ART programme has grown rapidly, and resulted in substantial 
positive change. Through improvements in the prevention of mother-to-child 
transmission (PMTCT) programme, vertical transmission was reduced from 15% in 
2009 to 4% in 2014, averting an estimated 370 000 new childhood HIV infections.[2] 
The 2013 national guidelines further expanded paediatric access to ART by 
broadening initiation criteria to include all HIV-infected children younger than 5 
years of age. By 2014 almost half of all HIV-infected children in the country were 
accessing ART, an increase from just 11% in 2009.[2] 
 
In the push for rapid scale-up of ART provision and improvement in ART coverage, 
the South African government adopted a public health approach to HIV care. Central 
to this approach are two closely linked concepts of task shifting and decentralization. 
Task shifting entails ‘lower’ cadres of health care providers, and sometimes non-
professionals, taking over responsibilities previously held by doctors or ‘higher’ 
cadres of health workers.[3] Decentralizing care includes moving care from tertiary 
referral centres to health care centres, clinics, and even beyond clinics into 
communities  - closer to patient’s places of residence.[4]  For many patients this has 
required a process of down-referral to sites with less specialized health care facilities.   
 
The Western Cape paediatric ART programme has made considerable efforts to 
decentralize care of HIV-infected children. Between March 2004 and December 2015 
the number of clinics in the province treating children with ART increased from 11 to 
180, and the percentage of children receiving ART from the three Cape Town tertiary 
hospitals declined from 78% to 14.7%.[5,6] By 2007/2008 the ART coverage rate in 
the province had improved to over 95%, well exceeding the national average of 
37%.[7] This was a consequence of both significant gains in preventing mother-to-
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child-transmission of HIV as well as the expansion of the paediatric HIV programme 
into primary health care (PHC) settings. This decentralized model of care necessitated 
down-referral of large numbers of children from tertiary academic hospitals to 
community-based clinics. There is very little data on the outcomes of down-referred 
children, and optimal down-referral criteria have not been defined. The down-referred 
cohort from Red Cross War Memorial Children’s Hospital (RCWMCH) specifically, 
has never been studied. This study therefore assessed ART outcomes of a cohort of 
children down-referred from RCWMCH to two primary health care clinics and 
explored determinants of successful down-referral.  
Methods 
Setting 
The study was conducted at RCWMCH as well as two PHC clinics in Cape Town, 
one in Gugulethu and the other in Heideveld.  
RCWMCH is a tertiary facility that serves as a referral centre for the paediatric 
population of the Western Cape and surrounding provinces. HIV-infected children 
have been accessing ART through this service since 1998. Since 2006, in accordance 
with the provincial framework for managing HIV-infected children, clinically stable 
children have been actively down-referred, mainly to level 1 paediatric HIV clinics 
within the Cape Metropolitan area. Although down-referral criteria have not been 
formalized or standardized, attending clinicians are encouraged to identify clinically 
stable patients for down-referral. Down-referral is facilitated by clinicians 
telephonically arranging the first PHC clinic appointment and providing caregivers 
with a written clinical summary for clinic staff. 
Both Gugulethu and Heideveld clinics fall within the immediate drainage area of 
RCWMCH and are less than 10 km apart. Gugulethu clinic is a large, well-established 
clinic that has been providing a paediatric HIV service since 2003. By comparison, 
Heideveld is a much smaller clinic, which only began its paediatric ART outpatient 
service in 2010. Both paediatric HIV clinics are medical officer led.  
32	
Study design  
The hospital ART database was used to identify all children from the Gugulethu and 
Heideveld drainage areas who commenced ART at RCWMCH between 1 January 
2006 and 31 December 2012. Baseline characteristic of patients and their caregivers 
were retrospectively extracted from case record forms held by the infectious diseases 
clinic in order to compare those patients who were subsequently down-referred to the 
PHC clinics by 31 December 2012 with those who remained in care at RCWMCH.  
For the group of patients who had been down-referred to the PHC clinics, hospital 
folders were reviewed to extract further information relating to hospital admission 
diagnoses, length of follow up at RCWMH and clinical and virological parameters 
prior to the point of down-referral. CD4 percentage (CD4%) and viral loads (VLs) 
prior to down-referral were accepted within a window period of 6 months. 
At the PHC clinics data were again retrospectively collected from patient folders, 
including the time between down-referral and presentation at PHC, as well as 
outcomes at 6 and 12 months post down-referral. Measures included patient’s weight, 
and CD4% and viral load results. For 6- and 12-month CD4% and viral load results, 
the closest measure within a window period of 4-8 and 9-15 months respectively were 
used.  
Anthropometric measurements such as weight and height were converted to gender 
specific weight-for-age z-scores (WAZ), height-for-age z-scores (HAZ) and weight-
for-height z-scores (WHZ) scores, according to the 2000 CDC growth charts.[8]
Moderate underweight for age, stunting and wasting were defined as WAZ, HAZ and 
WHZ between -2 and -3 Z-Scores, below -3 were defined as severe underweight, 
stunting and wasting. Specific outcomes measured at 6 and 12 months post down-
referral included mean WAZ, WAZ category, median CD4%, the proportion of 
children with severe immunodeficiency as defined by the World Health 
Organization,[9] the proportion who were virologically suppressed (defined as a viral 
load <400 copies/mL), and at 12 months the proportions who remained in care or had 
been lost to follow up were documented. Viral load was measured by the Abbott 
Realtime HIV-1 assay in copies/mL and converted to log10 values, and CD4 absolute 
counts and percentages were quantified by the PanLeucogated method.[10,11]  
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Data analysis 
Data were collected on a standardized data capture sheet and inputted into Microsoft 
Excel. Data were analysed using Stata software (Stata/IC 13.0 for Windows, 
StataCorp LP, USA). Mean ± standard deviation (SD) or median and interquartile 
range (IQR) were used to describe normally- and non-normally distributed data 
respectively. Student’s t-test was used to compare normally distributed data and 
Wilcoxon sum rank test for skewed data.	Categorical data were compared using chi-
squared or Fisher’s exact test, as appropriate  
Univariate analyses using unadjusted risk ratio (RR) and 95% confidence intervals 
(95% CI) were performed to identify potential factors associated with retention in 
care at the PHC clinic at 12 months post down-referral. There were no significant 
factors on univariate analysis therefore multivariable analyses were not completed. 
Ethics considerations 
The study was approved by the Human Research Ethics Committee, Faculty of Health 
Sciences, University of Cape Town (HREC REF: 246/2013) and the Western Cape 
Department of Health. Patient consent was not obtained because the data was 
collected and collated retrospectively. The study was completed in accordance with 
the Declaration of Helsinki.  
Results 
A total of 231 children from Heideveld and Gugulethu drainage areas were identified 
who had initiated ART at RCWMCH within the study time period. Of these, 119 were 
subsequently down-referred to the PHC clinics for ongoing care. Three down-referred 
patients were excluded from the analysis; 1 had initiated ART prior to presentation at 
RCWMCH, and 2 were not actively down-referred but rather lost to follow-up 
(LTFU). Data from the remaining 116 children (study cohort) were analysed.  
Baseline characteristics 
The median age of the study cohort at ART initiation was 11 months; 52.6% (61/116) 
were <12 months of age. Moderate to severe wasting and stunting were present in 
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29.2% and 39.3% of the cohort respectively. Advanced clinical disease (WHO 
clinical stage 3 or 4) was present in 90.2% of the cohort. At the time of initiating ART 
18.1% (21/116) of the study cohort was on treatment for tuberculosis (TB), 23.8% 
(5/21) of whom were treated for extra-pulmonary TB. The median CD4% was 17.6%, 
and 68.7% met the WHO definition of severe immunodeficiency.[9] Baseline 
characteristics of the study cohort were similar to the characteristics of HIV-infected 
children from Gugulethu and Heideveld who were initiated on ART at RCWMCH 
during the study period but were retained in care at the hospital (summarized in Table 
1). 
The primary caregiver for the majority (87.1%) of children in the study cohort was the 
mother, whilst 6% were maternal orphans. Less than 40% of mothers received any 
PMTCT intervention and only 12.9% were receiving ART at the time of their child’s 
initiation.  Almost half of the cohort lived in informal housing and 52.6% were 
accessing government grants. Table 2 summarizes the primary caregiver and social 
characteristics of the study cohort and non-down-referred children. The only 
statistically significant difference between these groups was the proportion of literate 
primary caregivers (66.4% vs. 72.3%, p=0.01). As there was a large amount of 
missing data for this variable it is unlikely to be clinically significant. 
HIV diagnosis and hospitalisation  
The majority of the cohort (79/116, 68.1%) had undiagnosed HIV infection prior to 
referral to RCWMCH, only 19.8% (23/116) were previously diagnosed at a PHC 
clinic, the remainder having been diagnosed at other hospitals or private doctors. Not 
all children required hospital admission, 13.9% (16/115) were managed exclusively 
on an outpatient basis at the outpatient HIV clinic (OHC). For the 99 children who 
were admitted to hospital, the mean ± SD length of stay was 19 ± 13.7 days and the 
most common admission diagnoses were acute lower respiratory tract infection 
(52.5%) and diarrhoeal disease (36.4%). The majority of children were managed in 
the general medical wards (71/98, 72.4%), however 18.4% required an intensive care 
unit (ICU) admission during their stay. Of the admitted children, 69.7% (69/99) were 
initiated on ART during hospitalisation, 15.9% (11/69) of whom whilst still in ICU. 
The other 30.3% (30/99) initiated ART during follow-up at the OHC.  
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ART management prior to down-referral  
All children in the study cohort were initiated on ART at RCWMCH. The time 
between HIV diagnosis and ART initiation of these children declined progressively 
from a median of 414 days for those diagnosed before 2005, to 15 days for those 
diagnosed in 2011/2012, a decrease of 96.4%.  
Of the children who required hospitalisation, 21.2% (21/99) were initiated on ART 
and down-referred to PHC clinics to continue their treatment at the time of discharge. 
The remaining 95 children were followed up at the OHC at RCWMCH for a median 
duration of 320 days (IQR: 189 – 685), with a mean ± SD number of 11.9 ± 8.4 clinic 
visits prior to down-referral, and 26.6% (25/94) of the cohort having at least 1 
hospital admission during follow-up. The median age at down-referral was 25.8 
months (IQR: 12.2 - 52.1). At down-referral 72.6% (69/95) of the cohort had a 
documented viral load within the preceding 6 months. Of these, 79.7% (55/69) were 
virally suppressed. Five children who had defaulted ART while attending OHC at 
RCWMCH were down-referred to re-start therapy at the referral clinic.  
Outcomes after down-referral  
At the PHC clinics folders for 6 patients were not found – so they were excluded from 
subsequent analysis. Once down-referred, 16 children did not arrive at the designated 
PHC, accounting for 64% (16/25) of all children LTFU within 12 months of down-
referral. Furthermore, although the median time between down-referral and 
presentation at the PHC was 26 days (IQR: 19.3 – 30.8), 11.7% (11/94) of those who 
did arrive took longer than 8 weeks (median 73 days, IQR: 64.5 – 106) to present to 
the PHC clinic. At down-referral 24.5% (27/110) of patients were either LTFU or had 
a probable treatment interruption. 
Twelve months after down-referral 68.2% (75/110) of patients remained in care at the 
designated PHC clinic, a further 6.4% (7/110) had been transferred out to other clinics 
and 1.8% (2/110) were back in care at RCWMCH. One patient (0.9%) had died, and 
25 others (22.7%) had been LTFU. Of those LTFU, 52% (13/25) were under 12 
months of age at the time of ART initiation.   
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Response to ART at down-referral clinics  
The 75 children who remained in care at the designated down-referral clinics showed 
sustained clinical and immunological response to ART over the 12 months of follow-
up (table 3).  
The number of children with moderate to severe underweight for age declined 
steadily from 50.7% (38/75) at initiation to 8% (6/75) 12 months after down-referral, 
p<0.001, and the percentage of children with severe immunodeficiency declined from 
69.3% to 1.3%, p<0.001. The median CD4% at down-referral had increased from 
17% at initiation to 31.2%, p<0.001, and this was sustained over 12 months of follow-
up in the PHC clinics. Similar rates of viral suppression were documented at down-
referral (38/75, 50.7%) and 12 months post down-referral (41/75, 54.7%), p=0.62.  
However, if only those children with documented viral loads are considered, rates of 
viral suppression were much higher both at down-referral (38/44, 86.4%) and 12 
months later (41/54, 75.9%).  
Despite these markers of improvement, 14.7% (11/75) of the cohort required at least 1 
hospital admission during the first year of follow up after down-referral. 	
Predictors of Retention in Care  
On univariate analysis no significant risk factors of retention in care at the two 
designated PHC clinics 12 months after ART initiation were identified (Table 4). 
Discussion 
The present study showed that for children who remained in care at the designated 
PHC clinics, clinical and immunological gains achieved on ART were sustained for at 
least 12 months after down-referral, and were consistent with results from larger 
studies in similar cohorts.[12,13] It has also shown, however, significant negative 
outcomes associated with the down-referral process – with 22.7% of the study cohort 
LTFU, 64% of whom never presented to the designated referral clinics and a further 
11.7% delaying their initial clinic appointment by a median of 73 days. In a study 
conducted in Thailand, of 168 children down-referred from a tertiary hospital to 
several community hospitals, none were LTFU during a median follow-up time of 18 
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months.[14] This perfect retention in care can be attributed to the intensive support and 
adherence counseling provided after down-referral, ongoing involvement of the 
referral team who provided active mentorship and clinical support to the treating 
teams in the community hospitals as well as 6-monthly clinical reviews of the down-
referred children at the tertiary referral hospital.[14] By contrast, the support available 
in our study was much less intensive, consisting of telephonic support for clinicians 
caring for HIV-infected children at the PHC clinics, and monthly clinical mentoring 
visits by an infectious diseases sub-specialist from RCWMCH.  
Another difference between our study and the Thai study is the age of the children. In 
the Thai study, the median age at initiation was 8.6 years compared to 11.0 months 
for our cohort. In a study of more than 5000 infants (<12 months of age) initiated on 
ART in Southern Africa, the 3-year mortality and LTFU estimates were 16% and 
29% respectively.[13] These results suggest that HIV-infected infants remain 
extremely vulnerable during the initial period on ART. Given that more than 50% of 
the down-referred children were infants at ART initiation this may partly explain the 
LTFU prevalence in our study.  
Movement of patients between Cape Town and other parts of South Africa without 
the knowledge of the attending clinician is a common occurrence. This is another 
possible factor contributing to LTFU in our study. It is possible that some of the 
LTFU children continued care at other HIV clinics in Cape Town or in the rest of 
South Africa. Our results suggest that the process of transitioning care from one site 
to another is inherently vulnerable, therefore greater attention should be given to 
monitoring down-referred children and strengthening the support provided to them 
and their caregivers. This could be done through more formalized communications 
with referral sites or even telephonic contact tracing of patients after down-referral.    
In order to minimize risks associated with down-referral it is imperative that we try to 
understand the factors that contribute to a successful transfer and those that hinder this 
process. Unfortunately our study did not identify any specific factors associated with 
successful down-referral. An early study examining adult patient attitudes to 
decentralized HIV care raised concerns over confidentiality and stigma associated 
with treatment within the community.[15] Whilst no similar data exists for the 
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paediatric population, the issues of stigma and confidentiality are likely equally as 
important for the caregivers on whom they rely to take them to clinic for treatment. 
Further studies are needed to clarify whether this does indeed affect the success of 
down-referral in provision of paediatric ART.  Other factors that could be explored 
include distance to PHC clinic and formal down-referral criteria. 
Study strengths and limitations  
To our knowledge this is the first South African study that has followed a cohort of 
children receiving ART through the process of down-referral from a tertiary referral 
hospital to PHC clinics. It therefore provides a unique perspective on the impact of 
the down-referral process on paediatric ART provision under routine operational 
conditions. 
There are a number of limitations to this study. The small cohort size may have 
limited the ability to detect significant factors affecting retention in care. Secondly 
this study only looked at two of the PHC clinics that fall under RCWMCH drainage 
area, consequently the results are not necessarily generalisable. Furthermore, the 
study design did not allow for tracing of patients who were LTFU. It is possible that 
after down-referral some patients may have continued care at a PHC clinic other than 
the one they were referred to. If this were the case the study would have over 
emphasized negative outcomes of down-referral.  
Conclusion 
This study has shown that the greatest risk of LTFU and treatment interruption 
associated with down-referral in provision of paediatric ART occurs at the point of 
down-referral. Children who successfully navigate this transition in care show 
sustained clinical and virological improvements.  
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Tables and Legends 
Table 1: Patient characteristics prior to antiretroviral therapy initiation 
Study group Non down-referred group p-value
Number 116 112 










Age at initiation (in months), median (IQR) N = 116 
11.0 (3.8 – 38.3) 
N=112 
8.2 (3.7-50.6) 0.98 
WAZ, mean ± SD N=116 
-2.06 ± 1.6
N=111 
-2.4 ± 1.7 0.18 
WAZ categories, n (%) 












HAZ, mean ± SD N=107 
-1.8 ± 1.6
N=77 
-1.8 ± 1.6 0.9 













WHZ, mean ± SD N=106 
-1.2 ± 1.8
N=66 
-1.7 ± 2.5 0.14 





























CD4 absolute count, median (IQR) N=115 
585 (249 – 1067) 
N=112 
460.5 (240 – 1119.5) 
0.77  
CD4%, median (IQR) N=115 
17.6% (11,4 – 23) 
N=112 
17.5% (10.6 – 24.3) 
0.81 
% Severe immunodeficiency, n (%) N=115 
79 (68.7) 
N=112 
79 (70.5) 0.76 
Log10 viral load, median (IQR) N=101 
5.6 (5 – 6.4) 
N=105 
5.9 (5 – 6.6) 
0.38  






Table 2: Mother, primary caregiver and social characteristics at antiretroviral therapy 
initiation  
Study group Non down-referred group p-value















































































































Table 3: Longitudinal changes of the 75 children who remained in care at the 
designated down-referral clinics 12 months after down-referral 
Initiation At down-
referral 
6 Months after 
down-referral 
12 Months after 
down-referral 








Suppressed Viral Load, n (%) 
Yes 
No 
Unknown/ not done 












































WAZ categories, n (%) 
Mild – normal >-1 




















Table 4: Predictors of retention in care at the designated PHC clinic, 12 months 
after down-referral 




Age <12 months at ART initiation 41/75 19/35 1.01 [0.70 – 1,45] 
Advanced clinical disease (WHO stages 3 & 4) at 
ART initiation 
66/73 30/33 0.99 [0.87 – 1.13] 
Moderate or severe underweight at ART initiation 38/75 20/35 0.89 [0.62 – 1.28] 
TB co-infection at ART initiation 12/75 4/35 1.40 [0.49 – 4.03] 
Up-to-date immunization status at ART initiation 58/66 24/30 1.10 [0.90 – 1.34] 
ART initiation as hospital inpatient 47/75 21/35 1.04 [0.76 – 1.44] 
Mother as primary caregiver at ART initiation 63/75 31/35 0.95 [0.81 – 1.11] 
Formal (vs informal) housing at ART initiation 43/75 19/35 1.06 [0.74 – 1.52] 
Caregiver receiving grant at ART initiation 40/72 15/32 1.19 [0.78 – 1.81] 
Household treatment supporter at ART initiation 46/66 18/28 1.08 [0.79 – 1.49] 
Follow-up at RCWMCH for >6 months prior to 
down-referral 
50/75 21/35 1.11 [0.81 – 1.52] 
Suppressed viral load prior to down-referral 38/44 15/22 1.27 [0.93 – 1.73] 
Mother alive at 12 months post-down-referral 54/67 12/13 0.87 [0.72 – 1.06] 
RIC = retained in care 
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Chapter 3: Appendices 
Appendix 1:  The protocol  
Introduction 
In September 2000, the South African government along with 188 other member 
states signed the United Nations Millennium Declaration. As part of the Millennium 
Development Goals the government thereby committed to reduce by two thirds the 
under-five-mortality-rate (U5MR) between 1990 and 20151.  According to figures 
from both the UN and the Actuarial Association of South Africa (ASSA) the U5MR 
increased from 1990, peaked around the year 2000, and thereafter followed a slowly 
declining trend. Although there is ongoing controversy over the accuracy of these 
figures2 there is agreement that the current U5MR (estimated at 56/1000 live births3) 
remains unacceptably high, and far off the goal of 20/1000 by 2015. Furthermore, 
there is no longer any disagreement over the profound contribution the HIV/AIDS 
epidemic makes in hindering progress towards reducing childhood mortality.  In a 
speech to the National Assembly in May 2011, the Minister of Health, Dr Aaron 
Motsoaledi, attributed 35% of childhood mortality to HIV and AIDS4. In this same 
speech he briefly outlined government efforts and plans to address this “unacceptably 
high maternal and child mortality.” 
Government response to the HIV/AIDS epidemic is now firmly based on a public-
health approach to scaling up provision of Antiretroviral therapy (ART) as advocated 
by the World Health Organization (WHO).  One of the central features of this 
approach is the decentralisation of care5.  Between February 2010 and May 2011 the 
number of health centres providing ART in South Africa increased from 490 to over 
2200 and the number of nurses certified to provide ART increased from 250 to 20004.  
This expansion and decentralisation of ART provision facilitated the increase in the 
number of people receiving ART from 923 000 to over 1,4 million in the same time 
period. The paediatric population has historically been under-represented in those 
receiving ART. Recent data, however, suggests that paediatric coverage (defined as 
the number of children under 15 years commencing treatment in a given year divided 




substantially from 2% in 2002/2003 to 36% in 2007/20086. This reflects both the 
successes of the Preventing Mother to Child Transmission (PMTCT) programme as 
well as greater access to ART for the paediatric population. By the end of 2010 there 
was an estimated 108 682 children under the age of 15 receiving treatment, making 
the South African paediatric ART programme the largest in the world7. According to 
the WHO global report , this represented only an estimated 36% coverage. The ability 
to reach the government stated goal of initiating 80% of those in need and retaining 
70% of them in treatment at 5 years after initiation8, will depend heavily on the policy 
of ‘down-referral’ and decentralisation. 
 
As the rollout of ART in South Africa reaches ever-increasing numbers of people, so 
the focus on ‘task-shifting’ or decentralising care increases9. Furthermore, as the 
sustained survival benefits of treatment are realised, so the call to manage HIV as a 
chronic illness in primary healthcare (PHC) facilities grows10. Over the last few years 
the Western Cape Paediatric ART programme, in line with government policy, has 
been actively down-referring stable patients to PHC facilities.  Between March 2004 
and September 2006 the percentage of children receiving their ART from the three 
Cape Town academic hospitals declined from 78% to 38%, and the number of clinics 
treating children with ART increased from 11 to 4111.  By July 2012, less than 14% of 
children were still receiving treatment from tertiary hospitals and the number of 
clinics treating children with ART had increased to 13412. In a retrospective review of 
over 1700 children commenced on ART in the Western Cape, Bock et al. 
demonstrated comparable rates of loss to follow up and virological suppression 
between children managed in PHC facilities and those in tertiary care13. There are 
however, very few studies that have specifically assessed the effects and outcomes of 
the down-referral process.     
 
Data from the adult literature have revealed a reluctance of patients to be down-
referred. In a study assessing patient attitudes to decentralisation, despite 
acknowledging the advantages of down-referral, namely savings of time and transport 
costs, patients still preferred attending a centralised treatment centre. They cited lack 
of confidentiality and poor nurse attitudes at local clinics as well as availability of 
ancillary services at the central hospital14. Despite this finding, comparable short-term 




demonstrated in a similar population in Soweto15.  In this matched cohort analysis 
patients became eligible for down-referral after 11 months of treatment if they were 
clinically well, with undetectable viral loads, CD4 cell counts ≥ 200cells/µl and no 
opportunistic infections. Over 65% of eligible patients were not down referred – and 
it is unclear as to whether this is because they refused or were not offered down-
referral. Although the outcomes of this study seem encouraging, 
data presented at the 16th International Workshop on HIV Observational Databases, 
showed a concerning increase in mortality in patients ‘transferred out’ from one level 
of care to another. In this cohort of 20116 patients (again an adult population) the 
mortality amongst those transferred out was 43% compared to 29% in the lost to 
follow up group16. Thus there are many remaining unanswered questions with regards 
to the outcomes of down-referral in the adult population – let alone the paediatric one. 
 
In the last 6 years (2006-2011) 1214 children have been initiated on ART at Red 
Cross Children’s War Memorial Hospital (RCWMCH), and 1260 were down referred 
to level 1 clinics for ongoing care. To date there has been no assessment of the 
outcomes of this group of children and the decision to down-refer is done on a case-
by-case basis at the clinician’s discretion. This study aims to assess the short-term 
outcomes of recently down-referred patients with the hope of establishing the safety 
and efficacy of the current programme of decentralisation of ART provision currently 
under way at RCWMCH. 
 
Aim  
• To describe the short-term outcome of HIV-infected children who were 
initiated on antiretroviral therapy at Red Cross War Memorial Children’s 
Hospital and recently down-referred to their local primary health care clinics 
for ongoing care 
 
Objectives:  
• To describe the clinical status and antiretroviral control of children prior to 
down-referral 
• To describe the clinical and virological status of children during the first 6 – 
12 months after down-referral 
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• To identify risk factors of successful down-referral
Methods: 
Setting: 
The study will be done at Red Cross War Memorial Children’s Hospital (RCWMCH) 
as well as two primary health care clinics – Gugulethu and Heideveld.  
RCWMCH is a 270 bed tertiary facility that serves as a referral centre for the 
paediatric population of the Western Cape and surrounding provinces. In 1990 an 
infectious diseases (ID) clinic was established at the hospital, and since 1998, HIV 
positive children have been accessing antiretroviral therapy (ART) through this 
service. More than 1900 children have been initiated on ART. Since 2006, in 
accordance with the provincial framework for managing HIV-infected children, 
clinically stable children have been actively down-referred, mainly to level 1 clinics 
within the Cape Metropolitan area.  
The timing of down-referral has been left to the attending clinician, who decides 
when a child is sufficiently clinically stable to be managed at a level 1 facility. 
Children deemed to be clinically unstable or who require sub-specialist care are 
retained by the ID service at RCWMCH. 
The immediate drainage areas of RCWMCH are the Klipfontein and Mitchells Plain 
sub-districts. Since 2010 RCWMCH has been actively supporting paediatric HIV 
clinics in the Klipfontein sub-district. Both the Gugulethu and Heideveld HIV clinics 
fall within this sub-district. Both clinics are less than 10 km apart. Gugulethu clinic is 
a large, well established clinic with support from a local Non Governmental 
Organisation (NGO). By comparison, Heideveld is a much smaller clinic which only 
began its paediatric ART programme in 2010. At the end of July 2012, Gugulethu and 
Heideveld clinics managed 390 and 41 children on ART, respectively. 
Study design & population 
Descriptive analysis of short term outcomes of all HIV-infected children commenced 
on ART at RCWMCH between 1 January 2006 and 31 December 2012 and who were 
subsequently down-referred to either Gugulethu or Heideveld clinics.  
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Study Plan:  
1. Using the hospital HIV database, identify all HIV-infected children, from the
Heideveld and Gugulethu drainage areas, who commenced ART during the
study period (1/1/2006 – 31/12/2012)
2. Of this initial cohort – identify all patients who had subsequently been down
referred for ongoing care by 31/12/2012 – the study group.
3. Assessment of baseline characteristics, comparing the study group to those
children from the same areas that remained in care at RCWMCH at the end of
the study period.
4. For patients in the study group:
• Hospital folder review – completing sections A and B of patient data sheet
(see appendix A)
• Clinic folder review (at Heideveld and Gugulethu PHC’s) to complete
section C of patient data sheet.
5. Analysis of data and description of findings
Data collection and entry: 
Data will be collected from the hospital’s HIV database and hospital records. This 
will allow for a comparison of baseline characteristics (including clinical, virological 
and social characteristics) between those patients who were down-referred in the 
study time period, and those who were retained in care, as well as a description of 
care before down-referral  
At Gugulethu and Heideveld clinics data will be collected on all the down-referred 
children from RCWMCH ART programme during the study period. Data collected 
will focus on compliance (measured by viral load and clinic attendance), retention in 
care, clinical characteristics (weight, intercurrent illnesses) and social parameters (e.g. 
relationship to primary caregiver, health of primary caregiver, distance to clinic). 
Refer part C of the data collection sheet. 
Data will be entered anonymously into an excel spreadsheet for analysis. 
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Data analysis: 
The data will be analysed using descriptive measures and conventional parametric and 
non-parametric comparative statistical methods. 
Outputs 
The analysed data will be presented at departmental meetings and scientific 
conferences, and be submitted for peer-review publication. 
This project will be used to complete an MMed (Paediatrics) by publication through 
the University of Cape Town 
Ethical considerations 
The study will be submitted for approval to the Departmental Research Committee, 
School of Child and Adolescent Health, University of Cape Town, the Human 
Research Ethics Committee, Faculty of Health Sciences, University of Cape Town, 
and the Western Cape Department of Health. Permission to access patient records at 
the level 1 clinics will be obtained form the operational manager in the Klipfontien 
sub-district as well as the clinic managers. 
The study will be done in accordance with the Declaration of Helsinki. 
Since the data is being collected retrospectively, consent will not be obtained from 
parents/legal guardians.  
The data sheets will include the names/folder numbers of patients to enable the 
researchers to check information from the hospital folders after data collection has 
been completed. Each name/folder number will be linked to a study number. Study 
numbers (but not names/folder numbers) will be entered on an electronic database for 
anonymous analysis and reporting. 
Risks to participants 
There are no risks to the participants in this study. Data will be collected 




Benefits to participants 
There are no direct benefits to the patients included in the study. 
 
 
Anticipated gain in scientific knowledge 
This study should contribute to understanding the down-referral process for HIV-
infected children initially treated at RCWMCH and identify factors associated with 





1. UNICEF MDG monitoring. http://www.unicef.org/statistics/index_24304.html
(Accessed 11 July 2012).
2. Kerber K, Tuaone-Nkhasi M, Dorrington RE, et al. Progress towards
Millennium Development Goal 4. Lancet 2012;379(9822):1193.
[http://dx.doi.org/10.1016/S0140-6736(12)60502-9]
3. Department of Health. Annual Performance Plan 2012/13 - 2014/15. 2012:1-
100. http://www.doh.gov.za/list.php?type=HIV and AIDS (accessed 11 July
2012).
4. Motsoaledi A. How we’re re-engineering the health system - Motsoaledi.
2011:1-15.
http://www.politicsweb.co.za/politicsweb/view/politicsweb/en/page71656?oid
=238984&sn=Detail&pid=71616 (accessed 11 July 2012).
5. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to
antiretroviral treatment against HIV in resource-limited settings. Lancet
2006;368(9534):505-10. [http://dx.doi.org/	10.1016/S0140-6736(06)69158-7]
6. Johnson L. Children Count - Children starting ART.
http://www.childrencount.ci.org.za/indicator.php?id=5&indicator=20.
(accessed 11 July 2012).
7. UNAIDS. Global report 2010.
http://www.unaids.org/globalreport/global_report.htm. (accessed 11 July
2012).
8. National Strategic Plan on HIV, STI’s and TB 2012 - 2016.
www.sahivsoc.org/upload/documents/National_Strategic_Plan_2012.pdf
(accessed	2	February	2013)
9. Zachariah R, Ford N, Philips M, et al. Task shifting in HIV/AIDS:
opportunities, challenges and proposed actions for sub-Saharan Africa. Trans
R Soc Trop Med Hyg 2009;103(6):549-558.
[http://dx.doi.org/10.1016/j.trstmh.2008.09.019]
10. Barker PM, Chb MB, Mccannon J, et al. Managing HIV as a chronic disease :
Using interactive data collection to improve clinical care. South Afr J HIV
Med 2004;	5(4)	7-11.
11. Eley B, Nuttall J. Antiretroviral therapy for children: challenges and
opportunities. Ann Trop Paediatr Int Child Heal 2007;27(1):1-10.
[http://dx.doi.org/10.1179/146532807X170448]
12. HIV/AIDS Directorate, Western Cape: Monthly ART statistics. 2012.
13. Bock P, Boulle A, White C, Osler M, Eley B. Provision of antiretroviral
53	
therapy to children within the public sector of South Africa. Trans R Soc Trop 
Med Hyg 2008;102(9):905-11. 
[http://dx.doi.org/10.1016/j.trstmh.2008.06.010] 
14. Mukora R, Charalambous S, Dahab M, Hamilton R, Karstaedt A. A study of
patient attitudes towards decentralisation of HIV care in an urban clinic in
South Africa. BMC Health Serv Res 2011;11:205.
[http://dx.doi.org/10.1186/1472-6963-11-205]
15. Brennan AT, Long L, Maskew M, et al. Outcomes of stable HIV-positive
patients down-referred from a doctor-managed antiretroviral therapy clinic to
a nurse-managed primary health clinic for monitoring and treatment. AIDS
2011;25(16):2027-2036. [http://dx.doi.org/10.1097/QAD.0b013e32834b6480]
16. Cornell M, Garone DB, Fox MP, et al. Survival Among Patients After
Transfer From ART Cohorts VS Pateients Not Transferred.  Unpublished
Data. Presented at 16th International Workshop on HIV Observational
















Normal Mild Moderate Severe





Place	of	care:	 S11 Ward ICU
























































































































































































































Appendix 3: Instructions to Authors (SAMJ) 
http://www.samj.org.za/index.php/samj/about/submissions#authorGuidelines 
Author Guidelines 
Accepted manuscripts that are not in the correct format specified in these guidelines will be 
returned to the author(s) for correction, and will delay publication. 
AUTHORSHIP 
Named authors must consent to publication. Authorship should be based on: (i) substantial contribution 
to conception, design, analysis and interpretation of data; (ii) drafting or critical revision for important 
intellectual content; or (iii) approval of the version to be published. These conditions must all be met 
(uniform requirements for manuscripts submitted to biomedical journals; refer to www.icmje.org). 
CONFLICT OF INTEREST 
Authors must declare all sources of support for the research and any association with a product or 
subject that may constitute conflict of interest. 
RESEARCH ETHICS COMMITTEE APPROVAL 
Provide evidence of Research Ethics Committee approval of the research where relevant. 
PROTECTION OF PATIENT'S RIGHTS TO PRIVACY 
Identifying information should not be published in written descriptions, photographs, and pedigrees 
unless the information is essential for scientific purposes and the patient (or parent or guardian) gives 
informed written consent for publication. The patient should be shown the manuscript to be published. 
Refer to www.icmje.org. 
ETHNIC CLASSIFICATION 
References to ethnic classification must indicate the rationale for this. 
MANUSCRIPTS 
Shorter items are more likely to be accepted for publication, owing to space constraints and reader 
preferences. 
Research articles (previously 'Original articles') not exceeding 3 000 words, with up to 6 tables or 
illustrations, are usually observations or research of relevance to clinical medicine and related fields. 
64	
References should be limited to no more than 15. Please provide a structured abstract not exceeding 
250 words, with the following recommended headings: Background, Objectives, Methods, Results, and 
Conclusion. 
Scientific letters will be considered for publication as shorter Research articles. 
Editorials, Opinions, etc. should be about 1000 words and are welcome, but unless invited, will be 
subjected to the SAMJ peer review process. 
Review articles are rarely accepted unless invited. 
Letters to the editor, for publication, should be about 400 words with only one illustration or table, and 
must include a correspondence address. 
Forum articles must be accompanied by a short description (50 words) of the affiliation 
details/interests of the author(s). Refer to recent forum articles for guidance. Please provide an 
accompanying abstract not exceeding 150 words. 
Book reviews should be about 400 words and must be accompanied by the publication details of the 
book. 
Obituaries should be about 400 words and may be accompanied by a photograph. 
Guidelines must be endorsed by an appropriate body prior to consideration and all conflicts of interest 
expressed. A structured abstract not exceeding 250 words (recommended sub-headings: Background, 
Recommendations, Conclusion) is required. Sections and sub-sections must be numbered consecutively 
(e.g. 1. Introduction; 1.1 Definitions; 2. etc.) and summarised in a Table of Contents. References, 
appendices, figures and tables must be kept to a minumum. 
Guidelines exceeding 8 000 words will only be considered for publication as a supplement to the 
SAMJ; the costs of which must be covered by sponsorship or advertising. The Editor reserves the right 
to determine the scheduling of supplements. Understandably, a delay in publication must be 
anticipated dependent upon editorial workflow. 
MANUSCRIPT PREPARATION 
Refer to articles in recent issues for the presentation of headings and subheadings. If in doubt, refer to 
'uniform requirements' - www.icmje.org. Manuscripts must be provided in UK English. 
Qualification, affiliation and contact details of ALL authors must be provided in the manuscript and 




Abbreviations should be spelt out when first used and thereafter used consistently, e.g. 'intravenous 
(IV)' or 'Department of Health (DoH)'. 
Scientific measurements must be expressed in SI units except: blood pressure (mmHg) and 
haemoglobin (g/dl). Litres is denoted with a lowercase 'l' e.g. 'ml' for millilitres). Units should be 
preceded by a space (except for %), e.g. '40 kg' and '20 cm' but '50%'. Greater/smaller than signs (> and 
40 years of age'. The same applies to ± and º, i.e. '35±6' and '19ºC'. 
Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160... 
Quotes should be placed in single quotation marks: i.e. The respondent stated: '...' Round brackets 
(parentheses) should be used, as opposed to square brackets, which are reserved for denoting 
concentrations or insertions in direct quotes. 
General formatting The manuscript must be in Microsoft Word or RTF document format. Text must 
be single-spaced, in 12-point Times New Roman font, and contain no unnecessary formatting (such as 
text in boxes, with the exception of Tables). 
ILLUSTRATIONS AND TABLES 
If tables or illustrations submitted have been published elsewhere, the author(s) should provide consent 
to republication obtained from the copyright holder. 
Tables may be embedded in the manuscript file or provided as 'supplementary files'. They must be 
numbered in Arabic numerals (1,2,3...) and referred to consecutively in the text (e.g. 'Table 1'). Tables 
should be constructed carefully and simply for intelligible data representation. Unnecessarily 
complicated tables are strongly discouraged. Tables must be cell-based (i.e. not constructed with text 
boxes or tabs), and accompanied by a concise title and column headings. Footnotes must be indicated 
with consecutive use of the following symbols: * † ‡ § ¶ || then ** †† ‡‡ etc. 
Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 1)'. Figure legends: 
Fig. 1. 'Title...' All illustrations/figures/graphs must be of high resolution/quality: 300 dpi or more is 
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numerical order of appearance in the Vancouver style (not alphabetical order). Approved 
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initials of all authors should be given; if there are more than six authors, the first three names should be 
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Wherever possible, references must be accompanied by a digital object identifier (DOI) link and 
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